Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014" provides data on the Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dysbetalipoproteinemia (Type III Hyperlipoproteinemia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dysbetalipoproteinemia (Type III Hyperlipoproteinemia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase 17
Clinical Trials by Trial Status 18
Unaccomplished Trials of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials 23
Clinical Trial Profiles 24
Clinical Trial Overview of Top Companies 24
AstraZeneca PLC 24
Clinical Trial Overview of AstraZeneca PLC 24
Sanofi 25
Clinical Trial Overview of Sanofi 25
Pfizer Inc. 26
Clinical Trial Overview of Pfizer Inc. 26
Blu Caribe 27
Clinical Trial Overview of Blu Caribe 27
Clinical Trial Overview of Top Institutes / Government 28
National Heart, Lung, and Blood Institute 28
Clinical Trial Overview of National Heart, Lung, and Blood Institute 28
Nanjing University 29
Clinical Trial Overview of Nanjing University 29
Ludwig-Maximilians-Universitat Munich 30
Clinical Trial Overview of Ludwig-Maximilians-Universitat Munich 30
Hospices Civils de Lyon 31
Clinical Trial Overview of Hospices Civils de Lyon 31
University Hospital, Bonn 32
Clinical Trial Overview of University Hospital, Bonn 32
Five Key Clinical Profiles 33
Appendix 48
Abbreviations 48
Definitions 48
Research Methodology 49
Secondary Research 50
About GlobalData 50
Contact Us 50
Disclaimer 51
Source 51


List of Tables
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2014* 6
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12
Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 13
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 16
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Terminated Clinical Trials, 2014* 19
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 21
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 24
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 25
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 26
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Blu Caribe, 2014* 27
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 28
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing University, 2014* 29
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ludwig-Maximilians-Universitat Munich, 2014* 30
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospices Civils de Lyon, 2014* 31
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Bonn, 2014* 32


List of Figures
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 13
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 16
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 21
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
GlobalData Methodology 49

Companies Mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Enabling Technological Platforms for Lab-on-Chip Applications  (Technical Insights)

Enabling Technological Platforms for Lab-on-Chip Applications (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • July 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686 biological ...

Biologicals in Oncology: Drug Pathway Analyzer 2014

Biologicals in Oncology: Drug Pathway Analyzer 2014

  • $ 3 675
  • Industry report
  • July 2014
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 1421 biological drugs known to affect more than 266 specific intracellular signaling pathways for the treatment ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.